ForwardVue Pharma CEO: “Short Path to the Clinic” for Retinal Disease Treatment

Source: Proactive

In an interview with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco, ForwardVue Pharmaceuticals CEO Alan Franklin, MD, PhD, who is an ophthalmologist, said the company’s lead molecule aims to treat retinal neovascular disease.

ForwardVue Pharmaceuticals’ lead molecule is a novel long acting ORAI1 blocker that acts both upstream and downstream of VEGF inhibition for durable administration up to 12 months to treat retinal neovascular disease. Target dosing will be 1-2 intravitreal injections per year.

To view the video, click here.

Related Content


COVID-19: Telemedicine in Retina
Source: Broadcasted - Tuesday, May 5th at 8PM ET


Can Ophthalmic Clinical Trials Proceed During COVID-19 Crisis?
Source: Broadcasted - Tuesday, April 28th at 8PM ET